Google’s DeepMind eyes clinical trials for AI-designed drugs in 2025
Google’s DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year.
2 Comments so far
A breakthrough in applying AI to medicine.
If Isomorphic Labs’ AI-designed drugs make it to clinical trials this year, it could signal a shift in how pharmaceuticals are developed—potentially speeding up the process and reducing costs. However, the real test will be whether these AI-designed compounds prove safe and effective in humans. If successful, it could revolutionize medicine, but regulatory and ethical challenges will still need to be addressed.
A breakthrough in applying AI to medicine.
If Isomorphic Labs’ AI-designed drugs make it to clinical trials this year, it could signal a shift in how pharmaceuticals are developed—potentially speeding up the process and reducing costs. However, the real test will be whether these AI-designed compounds prove safe and effective in humans. If successful, it could revolutionize medicine, but regulatory and ethical challenges will still need to be addressed.